Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Koen J. Hartemink"'
Autor:
Mandy Jongbloed, MD, Martina Bortolot, MD, Leonard Wee, PhD, Jarno W.J. Huijs, MD, Murillo Bellezo, PhD, Rianne D.W. Vaes, PhD, Frank Aboubakar Nana, MD, PhD, Koen J. Hartemink, MD, PhD, Dirk K.M. De Ruysscher, MD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100740- (2024)
This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (
Externí odkaz:
https://doaj.org/article/37a62727e6614b9ab0cb07a65edce6a3
Autor:
Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy for yet unknown reasons. Defin
Externí odkaz:
https://doaj.org/article/765f3c5d599a4883af3b95a3fce40f0d
Autor:
Mafalda Antunes-Ferreira, Silvia D’Ambrosi, Mohammad Arkani, Edward Post, Sjors G. J. G. In ‘t Veld, Jip Ramaker, Kenn Zwaan, Ece Demirel Kucukguzel, Laurine E. Wedekind, Arjan W. Griffioen, Mirjam Oude Egbrink, Marijke J. E. Kuijpers, Daan van den Broek, David P. Noske, Koen J. Hartemink, Siamack Sabrkhany, Idris Bahce, Nik Sol, Harm-Jan Bogaard, Danijela Koppers-Lalic, Myron G. Best, Thomas Wurdinger
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various cancer types. In this s
Externí odkaz:
https://doaj.org/article/9358e61d08a441cdb79204397fabd108
Autor:
Daan C. L. Vessies, Milou M. F. Schuurbiers, Vincent van derNoort, Irene Schouten, Theodora C. Linders, Mirthe Lanfermeijer, Kalpana L. Ramkisoensing, Koen J. Hartemink, Kim Monkhorst, Michel M. van denHeuvel, Daan van denBroek
Publikováno v:
Molecular Oncology, Vol 16, Iss 14, Pp 2719-2732 (2022)
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit. Identifying patients with minimal residual disease
Externí odkaz:
https://doaj.org/article/7c9a7ac9915a498c906ab5000c1e0443
Autor:
Pieter J.M. Joosten, MD, Toon A. Winkelman, MD, David J. Heineman, MD, PhD, Sayed M.S. Hashemi, MD, Idris Bahce, MD, PhD, Suresh Senan, MD, PhD, Marinus A. Paul, MD, PhD, Koen J. Hartemink, MD, PhD, Max Dahele, MbChB., PhD, Chris Dickhoff, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 5, Pp 100172- (2021)
Introduction: The role of salvage surgery for patients with locoregional (LR) recurrence or persistent SCLC after radical chemoradiotherapy (CRT) for limited-stage disease is not well established. We evaluated our experience. Methods: We conducted a
Externí odkaz:
https://doaj.org/article/20a76550f54c4611af878a98371fb8f5
Autor:
Stefano Trebeschi, Zuhir Bodalal, Thierry N. Boellaard, Teresa M. Tareco Bucho, Silvia G. Drago, Ieva Kurilova, Adriana M. Calin-Vainak, Andrea Delli Pizzi, Mirte Muller, Karlijn Hummelink, Koen J. Hartemink, Thi Dan Linh Nguyen-Kim, Egbert F. Smit, Hugo J. W. L. Aerts, Regina G. H. Beets-Tan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCheckpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in metastatic settings are still under research. Imaging offers distinctive advantages, providing whole-body infor
Externí odkaz:
https://doaj.org/article/ffb91a99007c454486ad28fdf5ff1d56
Autor:
Jana S. Hopstaken, Julianne C. de Ruiter, Ronald A.M. Damhuis, Adrianus J. de Langen, Judi N.A. van Diessen, Houke M. Klomp, Elisabeth G. Klompenhouwer, Koen J. Hartemink
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100404- (2021)
Objectives: Several treatment modalities are available for patients with stage I non-small cell lung cancer (NSCLC). Over the past decade, these treatment modalities have been further investigated and might have changed current treatment regimens. In
Externí odkaz:
https://doaj.org/article/f60f54ad10b3414f9748f599348911db
Autor:
Krijn K. Dijkstra, Kim Monkhorst, Luuk J. Schipper, Koen J. Hartemink, Egbert F. Smit, Sovann Kaing, Rosa de Groot, Monika C. Wolkers, Hans Clevers, Edwin Cuppen, Emile E. Voest
Publikováno v:
Cell Reports, Vol 31, Iss 5, Pp - (2020)
Summary: Clinical implementation of tumor organoids for personalized medicine requires that pure tumor organoids can be reliably established. Here, we present our experience with organoid cultures from >70 non-small cell lung cancer (NSCLC) samples.
Externí odkaz:
https://doaj.org/article/b469827b6c1c427c86f583c772baa165
Autor:
Rosa De Groot, Marleen M. Van Loenen, Aurélie Guislain, Benoît P. Nicolet, Julian J. Freen-Van Heeren, Onno J.H.M. Verhagen, Michel M. Van Den Heuvel, Jeroen De Jong, Patrick Burger, C.Ellen Van Der Schoot, Robbert M. Spaapen, Derk Amsen, John B. A. G. Haanen, Kim Monkhorst, Koen J. Hartemink, Monika C. Wolkers
Publikováno v:
OncoImmunology, Vol 8, Iss 11 (2019)
Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer. With the current treatment regimens, the mortality rate remains high. Therefore, better therapeutic approaches are necessary. NSCLCs generally possess many genetic mutati
Externí odkaz:
https://doaj.org/article/f448f39206b24f9d9d87e6d41805f604
Autor:
Martijn R. Groenendijk, Koen J. Hartemink, Chris Dickhoff, Leo M.G. Geeraedts Jr., Maartje Terra, Patrick Thoral, Sayed M.S. Hashemi
Publikováno v:
Respiratory Medicine Case Reports, Vol 13, Iss C, Pp 9-11 (2014)
High energy trauma may cause injury to tracheobronchial structures. This is sometimes difficult to diagnose immediately. Pneumomediastinum and (bilateral) pneumothorax seen on a CT-scan of the thorax may suggest possible damage to central airways. Em
Externí odkaz:
https://doaj.org/article/7a6a6bf3a163491a999f64c5f0c7e821